200+ Free BCOP Practice Questions

Pass your Board Certified Oncology Pharmacist exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

54-65% Pass Rate

200+ Questions

100% Free

1 / 200

Question 1

Score: 0/0

Which proto-oncogene, when mutated, is most commonly associated with non-small cell lung cancer (NSCLC) and is a target for tyrosine kinase inhibitors?

KRAS

EGFR

BRAF

ALK

to track

2026 Statistics

Key Facts: BCOP Exam

150

Total Questions

BCOP format

3h 40m

Exam Time

BCOP format

500/800

Passing Score

Scaled scoring

38%

Therapeutics Domain

Largest domain

$600

Exam Fee

BPS 2026

7 years

Certification Valid

Recertification cycle

The BCOP exam has a pass rate of approximately 54-65%. The exam uses 150 questions over 3 hours 40 minutes with scaled scoring (200-800, 500 passing). Content covers cancer biology, chemotherapy, targeted therapy, immunotherapy, supportive care, and emerging topics like CAR-T therapy, biosimilars, and precision medicine. BCOP certification requires recertification every 7 years. Eligibility requires PharmD + active license + 3 years oncology practice or PGY2 oncology residency within 7 years.

Sample BCOP Practice Questions

Try these sample questions to test your BCOP exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 200+ question experience with AI tutoring.

1Which proto-oncogene, when mutated, is most commonly associated with non-small cell lung cancer (NSCLC) and is a target for tyrosine kinase inhibitors?

A.KRAS

B.EGFR

C.BRAF

D.ALK

Explanation: EGFR (Epidermal Growth Factor Receptor) mutations are found in approximately 10-15% of NSCLC cases in Western populations and up to 40% in Asian populations. EGFR tyrosine kinase inhibitors (TKIs) like osimertinib, gefitinib, and erlotinib are first-line treatments for EGFR-mutant NSCLC. KRAS mutations are also common but were historically undruggable until recent KRAS G12C inhibitors.

2Which tumor marker is elevated in ovarian cancer and is used primarily for monitoring response to therapy and detecting recurrence?

A.CA 19-9

B.CEA

C.CA 125

D.AFP

Explanation: CA 125 (Cancer Antigen 125) is the primary tumor marker for epithelial ovarian cancer. It is elevated in approximately 80% of advanced ovarian cancers and is used to monitor treatment response and detect recurrence. It is not used for screening due to low specificity. CA 19-9 is primarily used for pancreatic cancer, CEA for colorectal cancer, and AFP for hepatocellular carcinoma and germ cell tumors.

3Which genetic syndrome is associated with mutations in the BRCA1 or BRCA2 genes and significantly increases the risk of breast and ovarian cancers?

A.Lynch syndrome

B.Hereditary Breast and Ovarian Cancer syndrome

C.Li-Fraumeni syndrome

D.Familial adenomatous polyposis

Explanation: Hereditary Breast and Ovarian Cancer (HBOC) syndrome is caused by pathogenic variants in BRCA1 or BRCA2 genes. BRCA1 carriers have up to 72% lifetime risk of breast cancer and 44% risk of ovarian cancer. BRCA2 carriers have approximately 69% and 17% risks respectively. Lynch syndrome is associated with colorectal and endometrial cancer (MLH1, MSH2, MSH6, PMS2, EPCAM).

4What is the mechanism by which p53 functions as a tumor suppressor gene?

A.Promoting cell cycle progression

B.Inducing apoptosis in response to DNA damage

C.Activating angiogenesis

D.Inhibiting DNA repair mechanisms

Explanation: The p53 tumor suppressor gene, often called the "guardian of the genome," induces cell cycle arrest and apoptosis in response to DNA damage. When activated by cellular stress, p53 can halt the cell cycle to allow DNA repair or trigger programmed cell death if damage is irreparable. Loss of p53 function is one of the most common genetic alterations in human cancers.

5Which molecular alteration defines Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)?

A.BCR-ABL1 fusion

B.JAK2 V617F mutation

C.FLT3-ITD mutation

D.PML-RARA fusion

Explanation: The Philadelphia chromosome results from a reciprocal translocation t(9;22)(q34;q11) creating the BCR-ABL1 fusion gene. This produces a constitutively active tyrosine kinase that drives CML pathogenesis. Tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib target this fusion protein. JAK2 V617F is associated with myeloproliferative neoplasms, and PML-RARA is found in acute promyelocytic leukemia.

6Which tumor marker is most appropriate for monitoring response to treatment in testicular germ cell tumors?

A.PSA

B.CA 125

C.LDH, β-hCG, and AFP

D.CEA

Explanation: Testicular germ cell tumors are monitored using a combination of tumor markers: lactate dehydrogenase (LDH), beta-human chorionic gonadotropin (β-hCG), and alpha-fetoprotein (AFP). AFP is elevated in non-seminomatous germ cell tumors, β-hCG in both seminomas and non-seminomas, and LDH indicates tumor burden. PSA is used for prostate cancer monitoring.

7What is the primary mechanism of carcinogenesis associated with chronic Helicobacter pylori infection?

A.Direct DNA damage by bacterial toxins

B.Chronic inflammation leading to cellular proliferation

C.Insertion of viral oncogenes

D.Inhibition of apoptosis via p53 mutation

Explanation: Chronic H. pylori infection causes chronic gastritis, leading to increased cellular proliferation, oxidative stress, and DNA damage over time. This chronic inflammatory environment promotes carcinogenesis. H. pylori is classified as a Class I carcinogen and is associated with gastric adenocarcinoma and MALT lymphoma. Eradication therapy can reduce cancer risk.

8Which gene fusion is characteristic of acute promyelocytic leukemia (APL) and is targeted by all-trans retinoic acid (ATRA)?

A.BCR-ABL1

B.PML-RARA

C.AML1-ETO

D.CBFB-MYH11

Explanation: APL is defined by the t(15;17) translocation creating the PML-RARA fusion gene. The PML-RARA protein blocks myeloid differentiation. All-trans retinoic acid (ATRA) overcomes this blockade, inducing differentiation of leukemic promyelocytes. Arsenic trioxide is also highly effective in APL. APL is a medical emergency due to risk of disseminated intravascular coagulation.

9What percentage of cancer cases are estimated to be attributable to inherited genetic mutations?

A.Less than 5%

B.5-10%

C.15-20%

D.25-30%

Explanation: Approximately 5-10% of all cancers are caused by inherited genetic mutations (germline mutations). The majority of cancers (90-95%) result from somatic mutations acquired throughout life due to environmental factors, aging, and random errors during DNA replication. However, understanding hereditary cancer syndromes is critical for risk assessment and prevention.

10Which angiogenic factor is the primary target of bevacizumab in cancer therapy?

A.EGFR

B.HER2

C.VEGF-A

D.PDGFR

Explanation: Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor A (VEGF-A), inhibiting angiogenesis (new blood vessel formation) required for tumor growth. It is approved for multiple cancers including colorectal, lung, ovarian, and glioblastoma. Common adverse effects include hypertension, proteinuria, and increased risk of bleeding.

About the BCOP Exam

The BCOP certification is a specialized credential for pharmacists specializing in oncology pharmacy. The exam covers 4 domains: Pathophysiology and Molecular Biology of Cancer (20%), Therapeutics, Patient Management, and Education (38%), Healthcare Systems and Professional Practice (17%), and Emerging Topics (25%). The exam consists of 150 items over 3 hours 40 minutes.

Questions

150 scored questions

Time Limit

3 hours 40 minutes

Passing Score

500/800 (scaled)

Exam Fee

$600 (Board of Pharmacy Specialties (BPS))

BCOP Exam Content Outline

20%

Pathophysiology and Molecular Biology of Cancer

Cancer biology, carcinogenesis, tumor markers, molecular targets, genetic testing, hallmarks of cancer, angiogenesis, and metastasis

38%

Therapeutics, Patient Management, and Education

Chemotherapy (anthracyclines, alkylators, antimetabolites, microtubule inhibitors), Targeted Therapy (EGFR, ALK, BRAF, HER2 inhibitors), Immunotherapy (checkpoint inhibitors, CAR-T), Supportive Care (antiemetics, growth factors, pain management), Clinical Trials

17%

Healthcare Systems and Professional Practice

Pharmacy operations, USP <797>/<800>, quality improvement, regulatory compliance (REMS), interprofessional collaboration, and medication safety

25%

Emerging Topics

Precision medicine, pharmacogenomics, liquid biopsy, CAR-T cell therapy, bispecific antibodies, antibody-drug conjugates, biosimilars, tumor-agnostic therapies, and minimal residual disease testing

How to Pass the BCOP Exam

What You Need to Know

Passing score: 500/800 (scaled)
Exam length: 150 questions
Time limit: 3 hours 40 minutes
Exam fee: $600

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

BCOP Study Tips from Top Performers

1Master molecular biology and genetic testing - understand EGFR, ALK, BRAF, KRAS, PIK3CA and their targeted therapies

2Know chemotherapy mechanisms, toxicities, and management (anthracycline cardiotoxicity, platinum neurotoxicity, etc.)

3Study immunotherapy mechanisms and immune-related adverse events (irAEs) management

4Understand supportive care: antiemetics (NCCN guidelines), growth factors, bone-modifying agents

5Stay current with emerging therapies: CAR-T, bispecific antibodies, ADCs, KRAS inhibitors, and tumor-agnostic approvals

Frequently Asked Questions

What is the BCOP pass rate?

The BCOP pass rate typically ranges from 54-65% depending on preparation and experience. The exam uses scaled scoring from 200-800, with 500 required to pass. Pass rates reflect the specialized nature of oncology pharmacy practice and the broad knowledge base required.

How many questions are on the BCOP exam?

The BCOP exam contains 150 questions total over 3 hours and 40 minutes. The exam covers 4 domains: Pathophysiology and Molecular Biology of Cancer (20%), Therapeutics and Patient Management (38%), Healthcare Systems and Professional Practice (17%), and Emerging Topics (25%).

What are the BCOP eligibility requirements?

To sit for the BCOP exam, you must have: (1) Graduated from an ACPE-accredited PharmD program, (2) Current, active pharmacist license, and (3) Either 3 years of oncology pharmacy practice OR completion of PGY2 oncology residency within the past 7 years.

How long is BCOP certification valid?

BCOP certification is valid for 7 years. Recertification can be achieved by either passing the exam again OR completing 100 hours of oncology-specific continuing education through BPS-approved programming.

What are the best study resources for BCOP?

Recommended BCOP study resources include: NCCN Guidelines, ASCO Education materials, BCOP Review Course by HOPA, Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice, and specialty pharmacy oncology resources. Plan for 4-6 months of study time. Focus on molecular biology, novel therapeutics, and supportive care.

How should I prepare for the BCOP exam?

Study systematically across all domains: Pathophysiology (20%), Therapeutics (38%), Healthcare Systems (17%), and Emerging Topics (25%). Focus on molecular targets, chemotherapy mechanisms, targeted therapy, immunotherapy, and supportive care. Stay current with new approvals and emerging therapies. Complete at least 2000 practice questions.